Ezrin Mediates Tethering of the γ-Aminobutyric Acid Transporter GAT1 to Actin Filaments Via a C-Terminal PDZ-Interacting Domain by Imoukhuede, P. I. et al.
Biophysical Journal Volume 96 April 2009 2949–2960 2949Ezrin Mediates Tethering of the g-Aminobutyric Acid Transporter GAT1 to
Actin Filaments Via a C-Terminal PDZ-Interacting Domain
P. I. Imoukhuede,†‡ Fraser J. Moss,‡ Darren J. Michael,§ Robert H. Chow,§ and Henry A. Lester‡*
†Bioengineering Division, ‡Division of Biology, California Institute of Technology Pasadena, California 91125; and §Zilkha Neurogenetic Institute
and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90089
ABSTRACT A high density of neurotransmitter transporters on axons and presynaptic boutons is required for the efﬁcient clear-
ance of neurotransmitters from the synapse. Therefore, regulators of transporter trafﬁcking (insertion, retrieval, and conﬁnement)
can play an important role in maintaining the transporter density necessary for effective function. We determined the interactions
that conﬁne GAT1 at the membrane by investigating the lateral mobility of GAT1-yellow ﬂuorescent protein-8 (YFP8) expressed
in neuroblastoma 2a cells. Through ﬂuorescence recovery after photobleaching, we found that a signiﬁcant fraction (~50%) of
membrane-localized GAT1 is immobile on the time scale investigated (~150 s). The mobility of the transporter can be increased
by depolymerizing actin or by interrupting the GAT1 postsynaptic density 95/Discs large/zona occludens 1 (PDZ)-interacting
domain. Microtubule depolymerization, in contrast, does not affect GAT1 membrane mobility. We also identiﬁed ezrin as a major
GAT1 adaptor to actin. Fo¨rster resonance energy transfer suggests that GAT1-YFP8 and cyan ﬂuorescent (CFP) tagged ezrin
(ezrin-CFP) exist within a complex that has a Fo¨rster resonance energy transfer efﬁciency of 19%5 2%. This interaction can be
diminished by disrupting the actin cytoskeleton. In addition, the disruption of actin results in a >3-fold increase in g-aminobutyric
acid uptake, apparently via a mechanism distinct from the PDZ-interacting protein. Our data reveal that actin conﬁnes GAT1 to
the plasma membrane via ezrin, and this interaction is mediated through the PDZ-interacting domain of GAT1.INTRODUCTION
The g-aminobutyric acid (GABA) transporter GAT1 (1),
a member of the SLC6 family of neurotransmitter trans-
porters, is a 12-transmembrane domain protein that aids in
terminating GABAergic synaptic signaling by transporting
GABA into cells. GAT1 is the predominant GABA trans-
porter in the brain, and is localized primarily on axons and
presynaptic terminals of GABAergic inhibitory neurons; it
is also expressed on astrocytes (2,3).
The uptake of each GABA molecule is coupled to the
cotransport of two Naþ ions and one Cl ion (4–6). The
complete time for one transport cycle is ~100 ms, which is
longer than the ~10-ms decay time constant of GABAergic
postsynaptic currents (7). This implies that each transporter
functions, at most, only once per synaptic event. To accommo-
date such functional constraints, a GAT1 density on the order
of 1000 transporters/mm2 is required (8). The actual measured
density of GAT1 molecules on several membranes, including
presynaptic boutons and axons, is 800–1300 transporters/mm2
(8). Therefore, a high membrane density of GAT1 underlies
the efficient clearance of GABA from the synaptic cleft and
from nearby extrasynaptic compartments. Knowing that
a high density of GAT1 on the membrane aids in clearance,
one may ask how GAT1 trafficking is regulated, and how
GAT1 is restricted among membrane compartments.
Some aspects of GAT1 trafficking have been studied, and
GAT1 insertion and retrieval time constants of 1.1 and
0.7 min1, respectively, were obtained through biotinylation
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the total GAT1 protein exists within a pool of transporters
adjacent to the membrane surface, acutely recycling in and
out of the plasma membrane. One third of this pool (11%
of the total GAT1) is resident in the plasma membrane in
the basal state. The trafficking rates and high number of
reserve GAT1 vesicles have the potential to affect GAT1
membrane density, and effectively increase GABA turnover.
We seek an understanding of the restriction of GAT1
mobility at the membrane and, by analogy, the restriction
of other SLC6 family transporters. To this end, we applied
fluorescence recovery after photobleaching (FRAP) to
measure GAT1 movement at the plasma membrane. FRAP
reveals both the time course and the mobile fraction for
protein movement, which are governed by passive diffusion,
by active processes, and by tethering within and near the
plane of the membrane. Furthermore, lateral intramembrane
diffusion is accepted as a form of protein trafficking, as
revealed through recent work on postsynaptic receptors
(the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor [AMPAR], N-methyl-D-aspartic acid receptor
[NMDAR], GABAA subunits, and glycine receptor) (9).
Lateral movement of AMPAR is not only faster than traf-
ficking by exocytosis, but it also accounts for a significant
amount of AMPAR exchange in dendritic spines (10).
Membrane protein mobility can be reduced or restricted
by linkage to the cytoskeleton (11,12). Therefore, we applied
cytoskeleton disruptors to determine how interactions with
actin and/or microtubules affect GAT1 mobility.
Membraneconfinement often occurs througha cytoskeleton
adaptor protein such as gephyrin, which serves as a scaffold
doi: 10.1016/j.bpj.2008.11.070
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which tethers the cystic fibrosis transmembrane conductance
regulator (CFTR) to actin (14). Therefore, we used Fo¨rster
resonance energy transfer (FRET) to determine the proximity
of an adaptor that may be involved in GAT1 restriction.
Altogether, the data reveal novel interactions between
GAT1, ezrin, and the actin cytoskeleton, and these interac-
tions require the GAT1 C-terminal postsynaptic density
95/Discs large/zona occludens 1 (PDZ)-interacting domain.
MATERIALS AND METHODS
Molecular biology
The green fluorescent protein (GFP) tagged mGAT1, mGAT10-GFP
construct was previously described, and was termed mGAT1-GFP (8). In
GAT10-GFP, added C-terminal residues (a linker followed by GFP) disrupt
the endogenous PDZ-interaction domain of GAT1 (C-terminal sequence,
AYI-CO2).
To generate the new fluorescent mutant, GAT1-YFP8, an intact PDZ-
interaction motif is added at the C-terminus, following the yellow fluores-
cent protein (YFP) moiety. The wild-type mGAT1 open reading frame
(ORF) is subcloned without its endogenous stop codon into the HindIII
and EcoRI sites of the pcDNA3.1(þ) expression vector (Invitrogen, Carls-
bad, CA) multiple cloning site (MCS). The YFP (Clontech, Mountain
View, CA) ORF into which we introduce the ‘‘monomeric’’ A206K muta-
tion (15) is then inserted in the frame with the mGAT1 ORF at the NotI
and XbaI sites of the pcDNA3.1(þ) MCS. This results in a 12-amino-acid
spacer between the end of the mGAT1 sequence and the beginning of the
fluorophore. The method of Geiser et al. for the integration of polymerase
chain reaction (PCR) fragments without the use of restriction enzymes
was modified, to amplify the final eight codons of the hGAT1 C-terminal
sequence from a source plasmid, using PfuTurbo Cx Hotstart polymerase
(Stratagene, La Jolla, CA) with 50 and 30 extensions that corresponded to
the 20–22 nucleotide regions that flank the intended site of insertion (16).
The PCR product from this first PCR is integrated in the frame immediately
after the YFP sequence, when used as the primers in a subsequent Quik-
Change II XL mutagenesis PCR reaction (100-ng product from the first
PCR reaction: 20 ng destination plasmid; Stratagene).
The cyan and yellow fluorescent protein (CFP and YFP respectively)
tagged ezrins, ezrin-CFP and YFP-ezrin, gifts from Dr. Forte and Lixin Zhu,
were described by Zhu et al. (17). The YFP-syntaxin, a gift of Dr. W. Almers,
was described by An and Almers (18).
Neuroblastoma-2a culture
Mouse neuroblastoma-2a (N2a) cells (ATCC, Manassas, VA) are grown at
37C in 95% air, 5% CO2, in N2a culture medium containing the following:
44.5% DMEM, 44.5% OptiMEM, 10% fetal bovine serum, and 1% peni-
cillin/streptomycin (10,000 IU penicillin, 10,000 mg/mL streptomycin)
(Invitrogen). After cells are grown to confluence, they are plated onto glass-
bottom dishes at a density of 3.5  105 cells/dish. Before plating, 14-mm
glass-bottom dishes (No. 0, Mattek, Ashland, MA) are coated with 0.05%
polyethylimine (PEI) (Sigma, St. Louis, MO), pH 8.4, in borate buffer.
The transfection of a total of 1 mg DNA per plate is performed 16–24 h later
with Lipofectamine and Plus reagent (Invitrogen). The composition of the
N2a imaging solution is (mM): 128 NaCl, 2.4 KCl, 25 HEPES, 1.2 MgCl2,
3.2 CaCl2, 1.2 KH2PO4, and 10 D-glucose (19).
Nocodazole treatment
Nocodazole (Sigma, St. Louis, MO) was dissolved in DMSO at a concentra-
tion of 5 mg/mL, and stored at 20C. We added 10 mM nocodazole to the
N2a culture medium, and cells were incubated for 16–24 h at 37C. This
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mally depolymerizing microtubules (20–22). Before imaging, N2a culture
medium was aspirated from cells, and cells were washed with imaging
solution containing 10 mM nocodazole. Cells were allowed to equilibrate
at room temperature for 30 min in the 10 mM nocodazole containing imaging
solution.
Latrunculin B and cytochalasin D treatment
Latrunculin B (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO and
stored at 20C at a stock concentration of 2.5 mM. We added 5 mM latrun-
culin B to the imaging solution, which was warmed to 37C before imaging.
Cells were washed with latrunculin B solution, and incubated for 1 h in the
solution before imaging. Cytochalasin D (Sigma, St. Louis, MO) was
dissolved in DMSO and stored at 20C at a stock concentration of
1 mg/mL. We added 1 mg/mL cytochalasin D to the imaging solution, and
warmed it to 37C. Cells were washed with the cytochalasin D solution,
and were incubated in the solution for 1 h before imaging.
GABA uptake
Uptake assays were performed using 12-well plates 48 h after transfection as
follows. Culture medium was aspirated, and cells were equilibrated for
10 min at room temperature in 1 mL Krebs-Ringer (KRH) buffer containing
(in mM): 130 NaCl, 1.3 KCl, 2.2 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 10 D-
glucose, and 10 HEPES, pH 7.4 (23). GABA uptake was initiated on aspira-
tion of the KRH buffer and the addition of 500 mL 2.5 mM GABA and 25 nM
[3H]GABA in KRH at room temperature. Uptake was terminated by four
rapid washes with KRHþGABA, using the same total GABA concentration
as during the uptake step. Cells were lysed in 1 mL 2% SDS in phosphate-
buffered saline (PBS). The [3H]GABA accumulation was assayed by liquid
scintillation spectrometry. Specific uptake was normalized to the total
protein in each well, as determined using the BCA protein assay (Pierce;
Rockford, IL). Actin disruption was performed by incubating cells with
5 mM latrunculin B for 1 h at 37C before uptake. We also included 5 mM
latrunculin B in both the KRH equilibration and the [3H]GABA buffers.
Microtubule and nuclear labeling with
TubulinTracker Green and Hoechst 33342
Microtubules were labeled according to the instructions of the supplier,
using TubulinTracker Green reagent for live-cell tubulin labeling (Molecular
Probes, Eugene, OR). Briefly, N2a nucleus was stained by the addition
of 10 mg Hoechst 33342; microtubules were stained with TubulinTracker
in Hanks’ Balanced Salt Solution by incubating for 30 min at 37C in
a 5% CO2 incubator. Cells were rinsed three times with warm imaging
solution before imaging.
Actin labeling with rhodamine phalloidin
A 14-mM rhodamine-conjugated phalloidin (Cytoskeleton, Denver, CO)
stock solution was prepared by dissolving the solid in methanol, and storing
at 20C. A fresh 4% solution of paraformaldehyde (Fluka, St. Louis, MO)
at pH 7.4 was prepared. The medium was aspirated from the dishes, and cells
were rinsed twice with 1  PBS. Fixation and staining were performed by
combining 4% paraformaldehyde, 0.1% Triton, and 2 units (5 mL) rhoda-
mine phalloidin per dish (10 min, room temperature). After fixation, cells
were washed twice with 1  PBS.
Confocal imaging
All FRAP experiments were performed on an inverted Zeiss LSM 510 Meta
(Carl Zeiss, Thornwood, NY), using a 63 Plan-Apochromat 1.4-NA oil-
immersion objective. Fluorescence was collected using an HFT KP 700/
514 nm beam-splitter (Carl Zeiss) and a 535–590-nm bandpass filter. The
detector gain was modified to allow for near-saturating conditions for a given
environment of GAT1.
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ROI. For footprint photobleach, a circular ROI was chosen with an area
of 9.4  0.9 mm2. For perimeter photobleach, a rectangular ROI was chosen
with an area of 12.5  1.2 mm2. The ROIs were photobleached at 25% laser
transmission, using the 514-nm laser line of a 40-mW argon laser. Photo-
bleaching was optimized to obtain ~80% photodestruction within the ROI.
Prebleach and recovery images were collected at 0.25% laser transmission
at 5-s intervals. Twelve-bit images were collected at a pixel resolution of
512  512. The pinhole diameter was set at 144 mm.
Dye-labeled N2a cells were imaged on an inverted Zeiss LSM 510 Meta
at 12 bits and a 512  512 pixel resolution. Stack slices were at 100-nm
intervals. Hoechst 33342 nuclear-labeled cells were imaged using a Plan-
Apochromat 100 1.4-NA oil-immersion objective, and were excited using
a two-photon laser tuned to 700 nm at 2.5% laser transmission. Fluorescence
was collected using the HFT KP 700/488 beam-splitter and FT 510 and BP
390-465 IR filters (Zeiss). Stack slices were at 100-nm intervals, and the
pinhole diameter was maximal (693 mm). TubulinTracker Green-labeled
N2a cells were imaged using a 100 1.4-NA oil-immersion objective. Cells
were excited with a 488-nm argon laser at 2.5% laser transmission. Fluores-
cence was collected with the HFT 488 beam-splitter and NFT 490 and BP
500-550 IR filters. Stack slices were at 100-nm intervals, and the pinhole
diameter was 213 mm. Rhodamine phalloidin-labeled N2a cells were imaged
with a Plan-Neuofluar 63 1.25 oil-immersion objective. Cells were excited
with a 543-nm helium neon laser at 7.75% laser transmission. Fluorescence
was collected using a 488/543 beam-splitter and NFT 545 and bandpass
565–615 filters. The zoom was 2, stack slices were at 550-nm intervals,
and the pinhole was 121 mm.
The FRET experiments were performed on a Nikon C1si laser-scanning
confocal microscope system (Nikon Instruments, Melville, NY), equipped
with spectral imaging capabilities and a Prior (Rockland, ME) remote-
focus stage, as described in Drenan et al. (24). Spectral FRET analysis
was performed as described in Nashmi et al. (25). Data are reported as
mean  SE.
FRAP analysis
Raw data were processed using algorithms written in-house (MATLAB,
The MathWorks, Natick, MA) to obtain the ratio fluorescence ¼
f ðtÞ  bðtÞ=ðfNBðtÞ  bðtÞÞ  ðf ðtoÞ  bðtoÞÞ. This expression was obtained
by subtracting the background fluorescence, b(t), correcting for the photo-
bleaching that occurs during recovery scanning by obtaining the fluores-
cence in a region not bleached, fNB (t), and normalizing to the prebleach
fluorescence intensity f(to). Normalized traces were averaged. Error bars
are reported as the standard error of the mean. Normalized data were fitted
to a double-exponential, five-parameter regression in SigmaPlot (Systat
Software, Inc., San Jose, CA) of the form FðtÞ ¼ Fbo  aebt  cedt , where
Fbo is the initial value of fluorescence after photobleaching, and a, b, c, and
d are constants obtained through fitting. The mobile fraction was determined
by applying regression data to the equation Mf ¼ FNFbo1Fbo , where Mf is the
mobile fraction and FN is the asymptote of the recovery curve. Values for
t1
2
were determined by applying regression data to the equations
Fh ¼ FNþFbo2 , t12 ¼ th  tbo, where Fh is the value for fluorescence when
half the recovery has occurred, th is the corresponding time for Fh, tbo isthe time after photobleaching when the first recovery image is obtained,
and t1
2
is the halftime of equilibration (26).
Real-time quantitative reverse-transcription PCR
Total RNA was prepared using the RNeasy Plus Mini Kit (Qiagen, Valen-
cia, CA). The RNA concentrations were quantified using the ND-1000
UV-Vis Spectrophotometer (Nanodrop Technologies, Wilmington, DE).
The primer and probe sets for Pals1, ezrin, b-actin, and g-actin were
designed by the Roche Universal Probe Library (UPL) Assay Design Center
(Roche Applied Science, Indianapolis, IN). Primer sets were obtained from
Integrated DNA Technologies (Coralville, IA). Table 1 displays the primer
and probe sets used for the real-time quantitative reverse-transcription PCR
(qRT-PCR) analysis of each gene in the N2a cells. One-step qRT-PCR was
performed using a hydrolysis probe mix, 96-well plates, and the LightCycler
480 RNA Master system (Roche Applied Science), according to the
supplier’s instructions. Briefly, samples along with serially diluted mRNA
(1:50, 1:100, 1:1000, 1:5000, and 1:10,000) were added to adjacent wells
of the plate, centrifuged for 2 min at 1500  g, and loaded into the instru-
ment. The one-step qRT-PCR was performed as follows: one cycle of
reverse transcription at 61C for 12 min; one cycle of denaturation at
95C for 30 s; 45 cycles of amplification at 95C for 10 s, 57C for 30 s,
and 72C for 1 s; and one cycle of cooling at 50C for 10 s. Serial dilutions
of mRNA provided the standard curves needed to quantify relative mRNA
concentrations.
Statistical analysis
Values are expressed as mean  SE, unless otherwise noted, and p < 0.05
is considered statistically significant.
RESULTS
In this study, we used an optimized mouse GAT1 that was
fused with YFP at the GAT1 C-terminus, followed by an
additional eight residues that included a PDZ domain bind-
ing site. This construct, GAT1-YFP8, produces the same
maximal GABA uptake and has the same GABA concentra-
tion dependence as the wild-type transporter (Fig. S1 in the
Supporting Material). In addition, the N2a assay system is
linear and nonsaturated (data not shown). We report else-
where that the GAT1-YFP8 transporter dimerizes correctly,
and is correctly trafficked to the plasma membrane. Further-
more, the surface/cytoplasmic expression ratio is sensitive, as
in neurons, to disruption of the PDZ interaction motif at the
C-terminus of GAT1. We therefore think that this assay
system closely resembles the native GAT1 transporter, ex-
pressed in the GABAergic neurons that constitute the nativeTABLE 1 Primers and UPL probes used in qRT-PCR analysis of Pals1, ezrin, b-actin, and g-actin expression in N2a cells
Protein
(gene accession no.)
Primer sequences
Roche UPL No.Forward (50/ 30) Reverse (50/ 30)
Pals1 (NM_019579.1) TGATTCCTAGTCAACAGATCAAGC GTCAAAATGAGCTTTCACATGG 51
Ezrin (NM_009510.2) AGCCGAATAGCCGAGGAC GTCACCCGGACGTTGATT 21
b-actin (NM_007393.1) CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 64
g-actin (NM_009609.2) GAGCACGCTGTAGATGAGAAAG GATCACTCAGTGGTGCTCACA 64
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mobility
The question often arises whether FRAP actually detects
lateral mobility, or whether it detects the fusion of vesicles
that are actively trafficking protein onto the membrane. To
address this question, we performed ‘‘whole footprint’’
FRAP. Fig. 1 A gives prebleach, postbleach, and recovery
images of a whole-footprint FRAP experiment. The post-
bleach image shows that >90% of the footprint surface
area is photobleached, and includes a line profile across the
bleached region. The ends of the line overlap nonpho-
tobleached regions. The kymograph in Fig. 1 B represents
the line profile, as shown in Fig. 1 A, over time, and it shows
that recovery occurs from regions not photobleached, with
fluorophore entering from the edges. This qualitative anal-
ysis indicates that FRAP largely reveals the lateral mobility
of GAT1. However, it is possible that the speckles that appear
A
B
C
FIGURE 1 Whole-footprint photobleach reveals lateral mobility. (A)
Confocal images of GAT1-YFP8 localized at the cell footprint show a pre-
photobleached and postphotobleached region of interest representing>90%
of the footprint surface area. Scale bar, 10 mm. (B) The kymograph is ob-
tained by measuring the intensity along the red line, which is a section of
the photobleached region. The line profile is plotted over time. The intensity
key shows that photobleached regions are represented by ‘‘cooler’’ colors,
and increased fluorescence is represented by ‘‘hotter’’ colors. (C) Diffusion
model is simulated using the Axelrod-Sprague pure-diffusion model and
data from GAT1-YFP8 footprint FRAP recovery. The GAT1-YFP8
recovery curve is not well-fitted by the Axelrod-Sprague pure-diffusion
model. The GAT1-YFP8 footprint FRAP recovery curve does fit a
double-exponential decay equation, FðtÞ ¼ Fbo  aebt  cedt, where a,
b, c, and d ¼ 3.3, 0.30, 0.45, and 0.033, respectively.Biophysical Journal 96(7) 2949–2960in the image after ~60 s represent some contribution from
vesicle exocytosis (9). In separate experiments, we visualized
and tracked individual vesicles containing GAT1; these will
be reported in a future study.
Fitting data to FRAP diffusion model
The diffusion model in Fig. 1 C is for a circular bleach spot,
derived by Axelrod et al. (27), and modified by Sprague et al.
(28) and Sprague and McNally (29). The model is as follows:
vf
vt
¼ DfV2f
tD ¼
t1
2
g
¼ u
2
Deff
s ¼ 1  A
FðtÞ ¼ e tD2t
h
Io
tD
2t

þ I1
tD
2t
i
 s
Based on the Axelrod-Sprague equation, g is a constant
equal to 0.88 for a circular beam with a Gaussian intensity
profile, tD is the recovery time constant, u is the radius of
the bleach spot, Deff is the effective diffusion coefficient,
and A represents the recovery asymptote for GAT1-YFP8.
Therefore, s is a correction that allows the diffusion model
to converge to the GAT1-YFP8 recovery asymptote. The
Axelrod-Sprague equation does not accurately describe
the behavior of GAT1-YFP8 recovery, suggesting that the
mobility of the transporter is not governed by pure diffusion.
In particular, the model exhibits sharp recovery at early time
points. The recovery of GAT1-YFP8 is well-fitted as double-
exponential decay (as described in Materials and Methods).
Because the double-exponential fitting more accurately
describes GAT1-YFP8 mobility on the time scale (~150 s)
of these experiments, t1/2 values are used in this study, rather
than diffusion coefficients.
Comparing and quantifying GAT1 mobility
To give a context to GAT1 mobility, we compare it with
minimally mobile and maximally mobile proteins, repre-
sented respectively by soluble YFP and by YFP-syntaxin1A,
a t-SNARE membrane protein (Fig. 2, A and B). Footprint
photobleach is chosen, because YFP is not a membrane
protein, and cannot be meaningfully analyzed with a perim-
eter photobleach. However, its mobility near the membrane
can be obtained by focusing near the coverslip. Within the
first seconds of detection, there is steep, unresolved recovery
of YFP to ~60% of its prebleach intensity; this limits the
quantitative analysis of the YFP mobile fraction (Fig. 2 C).
However, a qualitative observation of Fig. 2 C shows that
the YFP recovery asymptote is greater than that of GAT1-
YFP8, and by extrapolating the initial YFP photobleach to
20% (GAT1-YFP8 Fbo), we infer that YFP has a higher
mobile fraction than GAT1-YFP8. As shown in Fig. 2 B,
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FIGURE 2 Comparing GAT1 mobility with cytosolic
and membrane inserted proteins. Footprint FRAP was
performed on GAT1-YFP8 (not shown), (A) YFP, and
(B) YFP-syntaxin. (C) Recovery curves show that YFP,
a soluble cytosolic protein, has a faster recovery than either
of the membrane proteins. The initial YFP recovery was
faster than the resolution of detection. The membrane
proteins GAT1-YFP8 and syntaxin-YFP recovered at
similar rates.and as previously reported, YFP-syntaxin clusters to form
exocytosis docking sites at the membrane, so it is not ex-
pected to have high membrane mobility (30). YFP-syntaxin
has a mobile fraction of 65%, comparable to the GAT1-
YFP8 mobile fraction of 60% (Fig. 2 C).
Photobleach regions
Variations in imaging parameters, such as laser intensity,
bleach size/shape, and pixel dwell time, can affect the results
of quantitative photobleach experiments (31). To provide
additional confirmation of the FRAP results, GAT1 experi-
ments were performed by photobleaching the cell footprint
and perimeter, and comparing the trends seen between these
regions of interest (Fig. 3, A and B). The approximate size for
footprint photobleach is a circle with an area of 8 mm2
(Fig. 3 A). Perimeter photobleach is performed by focusing
the laser on a plane vertically midway through the cell,
and a rectangular section, including the cell membrane
(with an area of 13 mm2), is photobleached (Fig. 3 B). Perim-
eter photobleach recovery occurs in two dimensions, and the
membrane fluorescence in the confocal slice is a line repre-
sentation of this recovery. Footprint and perimeter photo-
bleach revealed GAT1-YFP8 mobile fractions of ~60%
and 50%, respectively (Fig. 3 C). These results suggest
that 40–50% of GAT1-YFP8 is immobilized on the time
scale (~150 s) of these experiments. Because a significant
fraction of surface GAT1 is immobile, we explored the
possibility of GAT1 tethering to the cytoskeleton.GAT1 interacts with cytoskeleton via actin but not
via microtubules
Fig. 4 A (left) displays microtubule distribution in an N2a cell
labeled with TubulinTracker 488. Fig. 4 A (right) includes
nuclear labeling with Hoechst 33342. Applying nocodazole
for 16–24 h maximally disrupts microtubules (20) (Fig. 4 B).
The FRAP traces show that nocodazole treatment has no
significant effect on either the recovery time constant or the
size of the mobile population (Fig. 4, C and D).
Rhodamine phalloidin labeling of actin filaments in N2a
cells confirms the actin disruption (Fig. 4, E and F). Modest
differences were evident between the untreated and the la-
trunculin B footprint photobleach traces, which translate to
a 20% increase in the mobile fraction (Fig. 4, G and I).
More pronounced differences in the untreated and latruncu-
lin B perimeter photobleach traces reveal a 60% increase in
the time constant for recovery, and a 20% increase in the
mobile fraction (Fig. 4, H–J). Cytochalasin D, another actin
disruptor, confirms the latrunculin B results, with an increased
t1/2 and an increased mobile fraction compared with the
untreated samples (Fig. 4, I and J).
Disrupting PDZ binding increases GAT1 lateral
mobility
Typically, actin binding occurs through an adaptor protein,
or by an interaction with a scaffolding protein such as
a PDZ protein (13,32–34). To determine whether PDZBiophysical Journal 96(7) 2949–2960
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FIGURE 3 Photobleached regions. FRAP prebleach and
postbleach images of N2a cells expressing GAT1-YFP8.
(A) Photobleaching is confined to cell footprint within
red circle (8 mm2). Scale bar, 3 mm. (B) Photobleaching
is confined to cell perimeter, within red rectangle
(13 mm2). Scale bar, 4 mm. (C) GAT1-YFP8 footprint pho-
tobleach gave a recovery t1/2 ¼ 10 s, and a mobile fraction
of 60%. GAT1-YFP8 perimeter photobleach gave
a recovery t1/2 ¼ 20 s, and a mobile fraction of 50%.binding links GAT1 to the actin cytoskeleton, we performed
quantitative photobleaching on GAT10-GFP, a fluorescent
GAT1 that cannot interact with PDZ proteins. In GAT10-
GFP, added C-terminal residues (a linker followed by
GFP) interrupted the endogenous PDZ-interaction domain
of GAT1 (C-terminal sequence, AYI-CO2). As a result,
homozygous GAT10-GFP knock-in mice showed a 70%
reduction in surface localization and synaptosomal GABA
uptake (8). Fig. 5 A illustrates the difference between the
two fluorescent GABA transporter constructs in this study:
GAT10-GFP lacks an intact PDZ-interacting domain, whereas
we inserted a PDZ-interaction domain to GAT1-YFP8, down-
stream of the YFP moiety.
FRAP was performed on N2a cells transfected with
GAT10-GFP. The GAT10-GFP was 30–40% more mobile
on the membrane than GAT1-YFP8, indicating that the
PDZ interaction domain contributes to GAT1 immobiliza-
tion (Fig. 5 B). Latrunculin B treatment shows that depoly-
merizing actin does not significantly affect the mobile
fraction (Fig. 5 B). Because the PDZ-binding domain of
GAT10-GFP was disrupted and this led to no interaction
with actin, we conclude that a PDZ-interacting domain in
GAT1 is necessary, either directly or indirectly, for GAT1-
actin interactions.Biophysical Journal 96(7) 2949–2960Actin disruption increases GABA uptake
Disruption of actin increases Naþ-dependent GABA uptake
in BGT1, a GABA transporter subtype that, like GAT1, is
expressed in the central nervous system, but unlike GAT1,
is also expressed in the kidney (35,36). To determine
whether actin disruption can increase GABA uptake by
GAT1, we performed GABA uptake on both actin-disrupted
and nontreated cells. Actin disruption increased the GABA
uptake of both GAT1-YFP8 and the poorly trafficking
GAT10-GFP (Fig. 5C). These statistically significant increases
amounted to a 3.4-fold increase in GABA uptake by GAT1-
YFP8, and a 3.1-fold increase in the much lower GABA
uptake by GAT10-GFP. Both increases were relative to non-
latrunculin B-treated controls.
Ezrin and Pals1 are expressed in N2a cells
The FRAP results indicate that GAT1 interacts with the cyto-
skeleton through the PDZ-binding motif. Another membrane
protein with this type of interaction is the Naþ/Hþ exchanger
isoform 3 (NHE3), which is restrained to actin through inter-
actions with the PDZ protein, the Naþ-Hþ exchanger regula-
tory factor (NHERF), and the adaptor protein ezrin (37).
To determine whether ezrin could link GAT1 to the
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FIGURE 4 GAT1 associates with
actin, but does not associate with micro-
tubules. (A, B) Microtubules are visible
after treatment with TubulinTracker
488. Right-hand panels display nuclear
labeling with Hoechst 33342. (B)
Microtubules are disrupted by treatment
with 10 mM nocodazole. Scale bars,
10 mm. (C, D) Traces display GAT1-
YFP8 fluorescence recovery in cells
with and without intact microtubules.
Cells are photobleached at the footprint
(C) and at cell perimeter (D). (E, F)
Actin is revealed after N2a cells are
treated with rhodamine-conjugated
phalloidin. (F) Actin filaments are dis-
rupted by treatment with latrunculin B.
Scale bars, 10 mm. Traces display
GAT1-YFP8 fluorescence recovery in
cells with and without an intact actin
network. Fluorescence is photobleached
at the cell footprint (G) and at the cell
perimeter (H). (I) GAT1-YFP8 mobile
fraction. Disrupting actin with 5 mM la-
trunculin B significantly increases the
amount of freely diffusing GAT1 on
the plasma membrane (p < 0.001,
t-test). The addition of 1mg/mL cytocha-
lasin D, another actin depolymerizer,
also significantly increases the mobile
fraction when probed with footprint
photobleach (p< 0.001, t-test). Depoly-
merizing microtubules with 10 mM no-
codazole does not affect the mobile frac-
tion of GAT1-YFP8. (J) GAT1-YFP8
time constant. Disrupting actin with
cytochalasin D or latrunculin B increases
the time for recovery with perimeter pho-
tobleach (p< 0.05, Mann-Whitney test).
Cytochalasin D treatment also signifi-
cantly increases the time constant for
recovery with footprint photobleach
(p < 0.05, Mann-Whitney test). Micro-
tubule disruption does not significantly
affect the time constant. GAT1-YFP8
footprint, n ¼ 18; GAT1-YFP8 þ noco-
dazole footprint, n ¼ 8; GAT1-YFP8 þ
latrunculin B footprint, n ¼ 12, GAT1-YFP8 þ cytochalasin D footprint, n ¼ 10; GAT1-YFP8 perimeter, n ¼ 12; GAT1-YFP8 þ nocodazole perimeter,
n ¼ 9; GAT1-YFP8 þ latrunculin B perimeter, n ¼ 12; GAT1-YFP8 þ cytochalasin D perimeter, n ¼ 10.cytoskeleton, we performed qRT-PCR, testing for the
expression of two genes: the PDZ protein known to interact
with GAT1, Pals1 (38), and the linker molecule ezrin. The
N2a cells expressed both ezrin and Pals1 mRNA at similar
levels (Fig. 6 A). The mRNA expression was normalized
to the b-actin control; g-actin was also used as a control,
with expression levels similar to those of b-actin (Fig. 6 A).
FRET suggests a GAT1-ezrin interaction
Figs. 6, B–H, display the results of FRET experiments that
combined donor recovery after acceptor photobleach withspectral unmixing. After the photodestruction of GAT1-
YFP8 with a 514-nm argon laser, there was a 23% increase
in ezrin-CFP fluorescence (Fig. 6, B and E). This increase
was seen most prominently along the cell membrane
(Fig. 6 B). The FRET efficiency observed between GAT1-
YFP8 and ezrin-CFP was 19%  2% (Fig. 6 F).
Inactive ezrin forms C-terminal to N-terminal dimers in
the cytosol (17,39). Therefore, the previously studied
FRET partners, ezrin-CFP/YFP-ezrin (17), were used as
a positive control. As expected, ezrin-CFP and YFP-ezrin
were localized in the cytosol, and exhibited a FRET effi-
ciency of 20%  2% (Fig. 6, D and F).
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FIGURE 5 GAT1-YFP8 and GAT10-GFP schematics,
FRAP, and GABA uptake. (A) Schematics of GAT1-
YFP8 and GAT10-GFP. GAT10-GFP is mostly found in
vesicles near the plasma membrane (8). This faulty traf-
ficking arises because the addition of linker and GFP
moiety interrupts the PDZ-binding motif. GAT1-YFP8
traffics properly due to the addition of eight amino acids
after the fluorescent protein, the final three amino acids
being a consensus PDZ-binding motif, AYI-CO2
. (B)
GAT10-GFP has a higher mobile fraction than GAT1-
YFP8 (p < 0.05, t-test). Disrupting actin does not signifi-
cantly affect the mobile fraction of GAT10-GFP, compared
with GAT10-GFP mobility in cells with intact actin.
GAT10-GFP footprint, n ¼ 9; GAT10-GFP þ latrunculin
B footprint, n ¼ 9; GAT10-GFP perimeter, n ¼ 12;
GAT10-GFP þ latrunculin B perimeter, n ¼ 10. (C) Dis-
rupting actin filaments through 1-h treatment with 5 mM
latrunculin B significantly increases GABA uptake by
GAT1-YFP8 and GAT10-GFP, relative to nontreated cells
(p < 0.001, Mann-Whitney test).Actin disruption diminishes GAT1-ezrin
interaction
GAT1-YFP8 photodestruction resulted in little or no increase
in ezrin-CFP fluorescence when actin was disrupted (Fig. 6,
C and E). Latrunculin B exposure produced a FRET effi-
ciency of 7%  5%, i.e., significantly lower than the FRET
value for both untreated and ezrin-CFP/YFP-ezrin control
samples (Fig. 6 F). These results indicate that actin depoly-
merization greatly destabilizes the interaction between
GAT1 and ezrin.
There is no GAT10-ezrin interaction
If the interaction between GAT1 and ezrin requires a PDZ-
binding motif, we expected to observe no such interaction
between ezrin and a GAT1 molecule that lacks such a motif.
GAT10-YFP provided an appropriate test. As expected, no
detectable increase in ezrin-CFP fluorescence accompanied
the photodestruction of GAT10-YFP (Fig. 6, G and H).
This result supports the idea that the interaction between
ezrin and GAT1 requires the binding motif.
DISCUSSION
This study establishes the role of lateral mobility in regu-
lating GAT1 localization, by quantifying the mobility of
GAT1 at the plasma membrane in an assay system resem-
bling the native mouse neurons that express mGAT1.
Previous studies on membrane proteins also used FRAP,
the most appropriate quantitative method for measuring
membrane protein mobility, in conjunction with manipula-
tions of PDZ-interaction domains (40–43).Biophysical Journal 96(7) 2949–2960Our FRAP experiments show that ~50% of membrane-
localized GAT1 molecules are mobile. Of the ~50% that
are immobile, a fraction associates with the actin cytoskel-
eton. This conclusion is based on a significant increase in
the mobile fraction of GAT1 in two experiments: 1), in cells
treated with pharmacological agents known to disrupt actin
filaments; and 2), in cells expressing a form of fluorescently
tagged GAT1 with a disrupted PDZ-interaction domain. The
magnitude of the increase in the mobile fraction of GAT1
was similar in both of these experiments. Moreover, the
mobility of GAT10-GFP, which has a disrupted PDZ-inter-
action domain, could not be increased further by treating
cells with an actin disruptor, more strongly implicating this
domain in GAT1-actin interactions.
The PDZ-interacting domain of GAT1 plays an important
role in tethering, and this fact indicates a link between GAT1
and actin. Most likely, this link is indirect, and is mediated by
a PDZ protein and a linker protein. Ion channels that bind to
PDZ proteins provide models for this interaction. PSD-95/
SAP-90, a member of the membrane-associated guanylate
kinase family of PDZ proteins, serves as a scaffold for the
NMDA receptor, thereby clustering it on the postsynaptic
membrane (44). This type of PDZ scaffolding also occurs
through the action of two known PDZ domain-containing
proteins (NHERF-1 and NHERF-2) on the CFTR (45).
The CFTR is linked to the actin cytoskeleton through inter-
actions between the PDZ domains of the proteins NHERF-1
and NHERF-2, and the actin binding protein, ezrin (14,40).
Biochemical investigations established interactions
between GAT1 and the PDZ protein, Pals1 (38), and
between Pals1 and the actin adaptor, ezrin (46). We showed
via reverse transcription-PCR that Pals1 and ezrin are
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FIGURE 6 Determination of expres-
sion of ezrin and Pals1 in N2a cells by
qRT-PCR, and an interaction between
ezrin and GAT1-YFP8 by FRET. (A)
mRNA levels of b-actin, g-actin, ezrin,
and Pals1, normalized to b-actin expres-
sion. One-step qRT-PCR shows that ez-
rin is expressed in N2a cells at levels
similar to those of PDZ protein Pals1.
(B–D) FRET results. Prebleaching and
postbleaching images of respective
CFP and YFP fused proteins. Images are
processed using Image J software with
the enhance-image plugin (Rasband,
W.S.; US National Institutes of Health,
Bethesda, MD). Scale bar, 5 mm. (E)
GAT1-YFP8 and ezrin-CFP interact, as
represented by the 25%  3% increase
in ezrin-CFP fluorescence that accom-
panies photodestruction of GAT1-
YFP8. The disruption of actin through
the addition of 5 mm latrunculin B
significantly decreased FRET between
ezrin-CFP and GAT1-YFP8. As a posi-
tive control, FRET between YFP-ezrin
and ezrin-CFP was performed, resulting
in a 26%  3% increase in ezrin-CFP
fluorescence that accompanied the pho-
todestruction of YFP-ezrin. (F) FRET
efficiency for ezrin-CFP/GAT1-YFP8 is
19%  2%, for ezrin-CFP/GAT1-YFP8
þ latrunculin B it is 7%  5%, and for
ezrin-CFP/YFP-ezrin it is 20%  2%.
Values are represented as the mean 
SE of 23 replicates. Significance was
determined by one-way analysis of vari-
ance with Tukey’s post hoc test (p <
0.05). (G, H) As a negative control,
experiments analogous to those in B
were performed with GAT10-YFP. No
detectable increase in ezrin-CFP fluo-
rescence accompanied the photodes-
truction of GAT10-YFP. Scale bar,
5 mm.expressed in our cell system. Through FRET, we also
showed that GAT1 and ezrin participate in a latrunculin
B-sensitive interactions. Furthermore, we observed no
FRET between GAT10-YFP and ezrin-CFP, which further
implicates the PDZ domain as essential to GAT1-actin inter-
actions.
A direct link between GAT1 and ezrin is unlikely, because
such direct linkage is typically stabilized via a triplet of posi-
tively charged residues in the juxta-membrane region
(47,48). GAT1 does contain lysines in the N-terminus (K7,
K26, K28, K33, K36, and K37). However, they are not adja-
cent, and this finding is not in accordance with the current
understanding of direct ezrin interactions. Further research
should elucidate whether these positive residues can partici-pate in ezrin binding. However, our data indicate that the
mobility of GAT1 is restricted by the actin cytoskeleton
joined by a PDZ protein (for which Pals1 is a strong candi-
date molecule in many neurons) and ezrin.
The illustrations in Fig. 7 summarize these results. Fig. 7 A
shows that an ezrin/PDZ complex can tether a membrane
protein via the C-terminal PDZ-interacting domain (AYI).
Disrupting actin abolishes the tetramolecular GAT1-PDZ
protein-ezrin-actin complex, either by separating GAT1
from its PDZ protein (Fig. 7, B1), or by separating the
ezrin-PDZ protein interaction (Fig. 7, B2). In either case,
this frees GAT1, conferring higher mobility within the
membrane. Finally, interrupting the endogenous C-terminal
PDZ-interacting domain of GAT1 with a linker and a GFPBiophysical Journal 96(7) 2949–2960
2958 Imoukhuede et al.moiety also increases the membrane mobility of GAT1
(Fig. 7 C). Additional members of the ezrin-radixin-moesin
family of filamentous actin-binding proteins may also play
a role in restricting GAT1 movements (34,49).
The t1/2 values for the recovery of untreated GAT1-YFP8
are 3–10 times lower than the t1/2 measured previously for
GAT1 trafficking to and from the plasma membrane (9), sup-
porting the idea that our measurements were not appreciably
distorted by cytoplasmic/surface trafficking. However, the
longest t1/2 measured after actin disruption, ~1 min, may
represent a component from cytoplasmic-surface interac-
tions, which is further supported by the speckling that occurs
after ~1 min in kymographic analysis of whole-cell photo-
bleach (Fig. S2). Recent studies of aquaporin-2 revealed
that actin reorganization may have a role in channel traf-
ficking, possibly because aquaporin-2 itself regulates the
local organization of actin (50). Further work should be per-
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FIGURE 7 Schematic of GAT1 interactions with Pals1, ezrin, and actin.
(A) Schematic of GAT1-YFP8 interaction with actin via ezrin and Pals1.
The additional PDZ domain after YFP moiety restores the interaction
between GAT1 and the PDZ protein. (B) The addition of 5 mM latrunculin
B disrupts actin, and reduces the interaction between ezrin and GAT1 either
by (B1) pulling away the GAT1-PDZ interaction, or (B2) reducing the inter-
action between ezrin and the PDZ protein. Altogether, this increases the
mobility of GAT1 on the membrane. (C) GAT10-GFP, a GAT1 with a dis-
rupted PDZ domain, is more mobile on the membrane, indicating that this
domain may also stabilize the GAT1-ezrin-actin interactions.Biophysical Journal 96(7) 2949–2960formed to determine whether these increases in t1/2 after
latrunculin B and cytochalasin D treatment suggest a role
for actin in GAT1 translocation, or whether these increases
are attributable to an increased effective molecular weight
of GAT1, by means of GAT1 retaining nonimmobilizing
interactions with other molecules (27–29).
Microtubules play well-established roles in protein traf-
ficking. Studies of the glycine receptor and GABAA receptor
subunits suggest that microtubules may also affect receptor
restriction to the plasma membrane via gephyrin scaffolding
(13,32,49,51,52). Our results indicate that neither GAT1
immobilization nor its membrane diffusion depend on micro-
tubules, after GAT1 has arrived at the plasma membrane.
Physiological signiﬁcance of GAT1 movements in
the membrane
One functional consequence of a disrupted actin cytoskel-
eton is increased GABA uptake, as evidenced by the
several-fold increase in GABA uptake after actin depolymer-
ization. Although Fig. 5 B also shows that depolymerizing
actin does not significantly affect the mobile fraction of
GAT10-GFP, Fig. 5 C shows that this treatment does
increase the relatively small GABA uptake of GAT10-
GFP, and by roughly the same ratio as for GAT1-YFP8.
This increase in GABA uptake upon actin depolymerization
suggests that actin plays an additional role in modulating
transporter function. Further experiments beyond the scope
of this study are required to determine whether the additional
modulation occurs via a syntaxin isoform that interacts with
both GAT1 and F-actin (53,54).
The GAT1 link to actin via ezrin may point to the role of
this interaction in the pathophysiology and/or treatment of
epilepsy. Although most studies of ezrin are focused on its
role in epithelial structure, organization, and signaling, ezrin
is also expressed in central nervous system neurons, and is
increased, at both the mRNA and protein levels, in certain
epilepsies. Ezrin is up-regulated in the hippocampus of
patients with mesial temporal-lobe epilepsy (55,56). Like-
wise, in the lithium-pilocarpine-treated rat model of
temporal-lobe epilepsy (57), ezrin is up-regulated within
48 h of seizure induction (58). Epilepsies associated with
malformations of cortical development, such as focal cortical
dysplasia (FCDIIb and FCDIIa) and gangliogliomas, are also
marked by neuronal ezrin accumulation (59). Although the
role of ezrin up-regulation in seizure progression has not
been formally identified, recent evidence points to the role
of ezrin as a downstream target in the phosphoinositide
3-kinase pathway (59,60).
The identification of interactions between GAT1, ezrin,
and actin, and our quantitative study using FRAP, contribute
to a further understanding of how transporters are clustered,
regulated, and confined on the cell surface. Because GAT1 is
an important drug target in the treatment of epilepsy,
continued research is needed to determine whether ezrin
Ezrin Tethers GAT1 to Actin Filaments 2959up-regulation and GAT1 tethering play a neurotherapeutic
role in epilepsy. Such protein interactions may lead to the
discovery of additional therapeutics targeting GAT1 func-
tion (61–64).
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